ViiV Healthcare receives approval from NMPA of China for Vocabria with Rekambys

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, announced that the National Medical Products Administration, NMPA, of China has approved ViiV Healthcare’s Vocabria used in combination with the Janssen Pharmaceutical Companies of Johnson & Johnson’s (JNJ) Rekambys for the treatment of HIV-1 infection. Prior to the recent marketing authorisation for rilpivirine long-acting injection, cabotegravir injection and tablets were approved in China in July 2023. Deborah Waterhouse, CEO of ViiV Healthcare, said: “At ViiV Healthcare, we are proud to be able to offer innovative solutions that meet the evolving needs of people living with HIV. The approval of cabotegravir injection and rilpivirine long-acting injection marks a step forward in helping to change the treatment experience for some people living with HIV in China who may have challenges with daily HIV therapies. We look forward to working closely with our partners in China to make this treatment available to those who could benefit from a long-acting regimen, part of our commitment to ensuring no person living with HIV is left behind.” This approval is based on data from three pivotal trials: the ATLAS studies, and the phase IIIb ATLAS-2M study, which collectively included more than 1,200 participants from 16 countries.